Erratum: Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials (Medicine (United States) 96:21 (e6944) DOI: 10.1097/MD.0000000000006944);Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes

Medicine (United States)

Volumn 96, Issue 21, 2017, Pages

  Yang, Yingying ^a   Chen, Shi ^a   Pan, Hui ^a   Zou, Yun ^b   Wang, Bo ^c   Wang, Guixia ^d   Zhu, Huijuan ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

FPG; genital tract infection; HbA1c; hypoglycemia; insulin; insulin dose; meta Analysis; SGLT2 inhibitors; urinary tract infection

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN;

ARTICLE; BODY WEIGHT; DIABETIC PATIENT; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; COMBINATION DRUG THERAPY; DIABETES MELLITUS;

DIABETES MELLITUS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85020393721     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007458     Document Type: Erratum

References (38)

1. Vehik K, Dabelea D. The changing epidemiology of type 1 diabetes: why is it going through the roof? Diabetes Metab Res Rev 2011;27:3-13.
2. Whalen K, Miller S, Onge ES. The role of sodium-glucose co-Transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther 2015;37: 1150-66.
3. Powell J, Miller SA, Taylor JR. Sodium-glucose cotransporter 2 inhibitors: The new option for diabetes mellitus management. South Med J 2015;108:82-90.
4. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 2015;66:255-70.
5. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol 2015;14:142.
6. Blevins T. Combination therapy for patients with uncontrolled type 2 diabetes mellitus: Adding empagliflozin to pioglitazone or pioglitazone plus metformin. Expert Opin Drug Saf 2015;14:789-93.
7. Saulsberry WJ, Coleman CI, Mearns ES, et al. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. Int J Clin Pract 2015;69:1221-35.
8. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015;38:403-11.
9. Monica Reddy RP, Inzucchi SE. SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 2016;53:364-72.
10. Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgrad Med 2016.
11. Araki E, Tanizawa Y, Tanaka Y, et al. Long-Term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015;17: 665-74.
12. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, doubleblind, placebo-controlled pilot study. Diabetes Care 2015;38:412-9.
13. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: A 4-week, randomized, placebocontrolled trial (EASE-1). Diabetes Obes Metab 2015;17:928-35.
14. Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-48.
15. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015;38:1181-8.
16. Suzuki K, Mitsuma Y, Sato T, et al. Comparison of combined tofogliflozin and glargine, tofogliflozin added to insulin, and insulin dose-increase therapy in uncontrolled type 2 diabetes. J Clin Med Res 2016;8:805-14.
17. Wilding JP, Norwood P, TJoen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-62.
18. Wilding JP, Woo V, Soler NG, et al. Long-Term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med 2012;156:405-15.
19. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab 2013;98:1845-59.
20. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: A 4-week, randomized, placebocontrolled trial (EASE-1). Diabetes Obes Metab 2015.
21. Bell DS. Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient. Case Rep Endocrinol 2015;2015:676191.
22. Buse J. Combining insulin and oral agents. Am J Med 2000;108(Suppl 6a):23s-32s.
23. Vouyiouklis M. Canagliflozin: improving diabetes by making urine sweet. Cleve Clin J Med 2013;80:683-7.
24. Kirkham JJ, Dwan KM, Altman DG, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
25. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24.
26. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab 2014;16:1102-10.
27. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013;11:43.
28. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928-38.
29. Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-8.
30. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33:1389-94.
31. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57: 3169-76.
32. Barnett AH. Complementing insulin therapy to achieve glycemic control. Adv Ther 2013;30:557-76.
33. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-Transport-2 inhibitors in type 2 diabetes: A meta-Analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:457-66.
34. Njomnang Soh P, Vidal F, Huyghe E, et al. Urinary and genital infections in patients with diabetes: how to diagnose and how to treat. Diabetes Metab 2016;42:16-24.
35. Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgrad Med 2016;128: 409-17.
36. Halimi S, Verges B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab 2014;40(6 Suppl 1):S28-34.
37. Nishimura R, Omiya H, Sugio K, et al. Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet. Diabetes Obes Metab 2016;18:702-6.
38. Goldenberg RM, Berard LD, Cheng AY, et al. SGLT2 inhibitorassociated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther 2016;38:2654-64. e2651.